Evidence map›Paper›PMID 38001086›Full record

ArticleNature communications2023

Nanoparticles exhibiting virus-mimic surface topology for enhanced oral delivery.

Zhentao Sang, Lu Xu, Renyu Ding, Minjun Wang, Xiaoran Yang, Xitan Li, Bingxin Zhou, Kaijun Gou, Yang Han, Tingting Liu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Zhentao Sang *School of Pharmacy, China Medical University, Shenyang, 110122, China.
Lu Xu *School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Renyu Ding *Department of Intensive Care Unit, The First Hospital of China Medical University, Shenyang, 110001, China.
Minjun WangSchool of Pharmacy, China Medical University, Shenyang, 110122, China.
Xiaoran YangSchool of Pharmacy, China Medical University, Shenyang, 110122, China.
Xitan LiDepartment of Intensive Care Unit, The First Hospital of China Medical University, Shenyang, 110001, China.
Bingxin ZhouSchool of Pharmacy, China Medical University, Shenyang, 110122, China.
Kaijun GouDepartment of Pathology, The First Hospital of China Medical University, Shenyang, 110001, China.
Yang HanInstitute of Tibetan Plateau, Southwest Minzu University, Chengdu, 610225, China.
Tingting LiuDepartment of Organ Transplantation and Hepatobiliary, The First Hospital of China Medical University, Shenyang, 110001, China.
Xuchun ChenDepartment of Organ Transplantation and Hepatobiliary, The First Hospital of China Medical University, Shenyang, 110001, China.
Ying ChengDepartment of Organ Transplantation and Hepatobiliary, The First Hospital of China Medical University, Shenyang, 110001, China. chengying75@sina.com.ORCID 0000-0002-0657-7551
Huazhe YangSchool of Intelligent Medicine, China Medical University, Shenyang, 110122, China. hzyang@cmu.edu.cn.ORCID 0000-0003-3177-6517
Heran LiSchool of Pharmacy, China Medical University, Shenyang, 110122, China. liheranmm@163.com.ORCID 0000-0003-2876-1525
China Medical University · CNFirst Hospital of China Medical University · CNShenyang Pharmaceutical University · CNSouthwest Minzu University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) No. 81903550
6 · The paper itself

Abstract

The oral delivery of nano-drug delivery systems (Nano-DDS) remains a challenge. Taking inspirations from viruses, here we construct core-shell mesoporous silica nanoparticles (NPs, ~80 nm) with virus-like nanospikes (VSN) to simulate viral morphology, and further modified VSN with L-alanine (CVSN) to enable chiral recognition for functional bionics. By comparing with the solid silica NPs, mesoporous silica NPs and VSN, we demonstrate the delivery advantages of CVSN on overcoming intestinal sequential barriers in both animals and human via multiple biological processes. Subsequently, we encapsulate indomethacin (IMC) into the nanopores of NPs to mimic gene package, wherein the payloads are isolated from bio-environments and exist in an amorphous form to increase their stability and solubility, while the chiral nanospikes multi-sited anchor and chiral recognize on the intestinal mucosa to enhance the penetrability and ultimately improve the oral adsorption of IMC. Encouragingly, we also prove the versatility of CVSN as oral Nano-DDS.

Indexed as

Drug CarriersNanoparticlesAnimalsDrug Delivery SystemsHumansIndomethacinPorositySilicon DioxideSolubilityDrug CarriersIndomethacinSilicon Dioxide

Identifiers

PMID38001086
PMCPMC10673925
OpenAlexW4388973083

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.